Literature DB >> 9265949

Mirtazapine: pharmacology in relation to adverse effects.

D Nutt1.   

Abstract

Mirtazapine is a new antidepressant that falls into the general class of receptor-blocking drugs rather than being an uptake or enzyme inhibitor. It can be described as a noradrenergic and specific serotonergic antidepressant (NaSSA). The unique pharmacology of mirtazapine means that it has a very different side effect profile from the tricyclic antidepressants, producing less alpha 1 adrenergic and muscarinic blockade, and the selective serotonin reuptake inhibitors (SSRIs) and the serotonin-noradrenaline reuptake inhibitors (SNRIs), causing much less nausea and sexual dysfunction by virtue of its blockade of 5-HT2 and 5-HT3 receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9265949     DOI: 10.1111/j.1600-0447.1997.tb05956.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  10 in total

1.  Neuropharmacological analysis of the role of the serotoninergic system in forming hyperalgesia in neurotic rats.

Authors:  M F Kudryashova; B V Andreev
Journal:  Neurosci Behav Physiol       Date:  2001 May-Jun

Review 2.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

3.  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.

Authors:  Jun Cao; Quchang Ouyang; Shusen Wang; Joseph Ragaz; Xiaojia Wang; Yuee Teng; Biyun Wang; Zhonghua Wang; Jian Zhang; Leiping Wang; Jiong Wu; Zhimin Shao; Xichun Hu
Journal:  Invest New Drugs       Date:  2020-02-08       Impact factor: 3.850

Review 4.  Newest Drugs for Chronic Unexplained Nausea and Vomiting.

Authors:  William L Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

5.  Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Authors:  Charles H K West; James C Ritchie; Katherine A Boss-Williams; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-27       Impact factor: 5.176

Review 6.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

Review 7.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

8.  A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction.

Authors:  Robert L. Barkin; Philip N. Chor; Bennett G. Braun; William A. Schwer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-10

9.  LPA1 receptor involvement in fibromyalgia-like pain induced by intermittent psychological stress, empathy.

Authors:  Hiroshi Ueda; Hiroyuki Neyama
Journal:  Neurobiol Pain       Date:  2017-04-17

10.  Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report.

Authors:  Antoine Yrondi; Laura M Fiori; Benicio N Frey; Raymond W Lam; Glenda M MacQueen; Roumen Milev; Daniel J Müller; Jane A Foster; Sidney H Kennedy; Gustavo Turecki
Journal:  Int J Neuropsychopharmacol       Date:  2020-02-01       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.